Biosimilarity Assessment

Get In Touch

The development of biosimilars requires rigorous attention to the manufacturing process due to its impact on the characteristics of the final product. That’s because the process occurs in living cells, which are inherently variable. We’re highly experienced in this kind of assessment.

 

When it comes to the development of biosimilars, the originator’s manufacturing process typically remains proprietary information. Because of this, biosimilarity assessments are both challenging and critical to get right. This is a specialist skill, and something our consultants are highly adept at.

 

Experts in assessing ‘live’ manufacturing

 

Drawing on our extensive experience across numerous biosimilar projects, we’ll help you perform a robust assessment of all critical aspects of your biosimilar development, including:

  • Structural and functional analytics
  • Impurity controls
  • Pharmacokinetics / pharmacodynamics
  • Immunogenicity
  • Product formulation and presentation
  • Sensitivity of the above to changes that may be made in the manufacturing process
  • Overall integrated development strategy with tailored clinical development if needed, building on the totality of evidence

 

Get In Touch

Insights Hub

Sharing insights, questioning norms, asking the right questions - we'll never lose sight of what you're striving for. Our insight and expertise will help you bring the most innovative therapies within reach of patients around the world.
Placeholder Image
28.06.23
Steve

Cell & Gene Therapy: Maximizing Commercialization Potential

How to Navigate the Less Obvious Barriers to Brining Advanced & Highly Targeted Treatments to

Start a conversation today

If you’re developing something truly ground-breaking, Biopharma Excellence is the nearest resource you’ll find to someone who’s been there before.

Socials:









    We are now Cencora PharmaLex 

    PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

    Know more